Enlivex Ltd. announced a cost reduction plan to focus resources on its Phase 2b clinical trial of Allocetra™ for moderate-to-severe knee osteoarthritis. The company is winding down non-clinical R&D, reducing its workforce by about 60%, and cutting management salaries to reduce cash burn. Positive Phase 1/2a results and FDA RMAT designation support the trial, with topline six-month data expected by mid-2027. This strategy aims to efficiently advance Allocetra™ as a potential treatment for a growing patient population with limited options.
Enlivex's cost reduction plan to focus on its Phase 2b trial of Allocetra™ provides context for health sector investors. For readers following health stocks, here is Pluang's market snapshot as of Oct 19, 2026 18:43 WIB: out of 150 priced health-sector US stocks, 68 rose and 54 fell today. Notable movers include Iovance Biotherapeutics Inc. (IOVA) at USD 13.80 with a 1-day change of +1.32% and a typical hold time on Pluang of 2 days, Sana Biotechnology Inc. (SANA) at USD 2.30 with a 1-day change of +1.32% and a typical hold time of 24 days, and Sanofi SA (SNY) at USD 40.09 with a 1-day change of -1.28% and a typical hold time of 94 days.
Bill Gross, a serial entrepreneur behind over 175 companies, has launched Idealab.ai, a platform using AI to generate and share over 1.2 million business ideas based on real-world problems. The platform aims to lower barriers to entrepreneurship by h...
The Portnoy Law Firm has launched an investigation into Cardinal Infrastructure Group for possible securities fraud following the company's Q2 2026 financial report. Cardinal revealed a decline in its gross profit margin to 10.8%, down from 13.9% the...
AIOS Tech Inc. announced an agreement to acquire SmartCore Holdings Limited in an all-stock transaction valued at approximately $100 million. The deal will issue 33.3 million AIOS shares to SmartCore's sellers, who will hold about 80% of AIOS shares ...
XBiotech announced positive results from the Phase II TASKIN trial, where their antibody vilamakitug combined with standard chemotherapy improved 12-month overall survival to 61.3% in refractory metastatic colorectal cancer patients, surpassing the s...
Proof and Circle Internet Group demonstrated a new system where AI agents can prove the identity of the person they represent using Proof's x401 open identity protocol and pay merchants in USDC via Circle's x402 payment protocol. This innovation addr...
